Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid (Q35910257)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 December 2010

Language	Label	Description	Also known as
English	Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid	scientific article published on 29 December 2010

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Retrospective Analysis of Clinical and Cost Outcomes Associated with Methicillin-Resistant Staphylococcus aureus Complicated Skin and Skin Structure Infections Treated with Daptomycin, Vancomycin, or Linezolid (English)

1 reference

Europe PubMed Central

11 August 2017

methicillin-resistant Staphylococcus aureus

0 references

1 reference

based on heuristic

inferred from title

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

author name string

Bradley M Wright

1

1 reference

Europe PubMed Central

11 August 2017

Edward H Eiland

2

1 reference

Europe PubMed Central

11 August 2017

publication date

29 December 2010

1 reference

Europe PubMed Central

11 August 2017

Journal of Pathogens

1 reference

Europe PubMed Central

11 August 2017

2011

1 reference

Europe PubMed Central

11 August 2017

347969

1 reference

Europe PubMed Central

11 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

A method for estimating the probability of adverse drug reactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

Health and economic impacts of antimicrobial resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

11 July 2018

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F347969

21 January 2018

Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3335594

24 September 2018

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05

1 reference

https://pubmed.ncbi.nlm.nih.gov/22567330

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4061/2011/347969

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35910257&oldid=1808562893"